Clinical Trials Logo

Clinical Trial Summary

The purpose of this open-label, randomized, controlled, Phase 1/2 study of the integrin inhibitor cilengitide is to evaluate the safety and efficacy of the combination of different regimens of cilengitide added to cisplatin, 5-fluorouracil (5-FU), and cetuximab in participants with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).

The Phase 1 part was conducted in dedicated study centers. In the Phase 2 part of this trial, cilengitide is administered at two different doses to two experimental groups. The third group will only receive cisplatin, 5-FU and cetuximab. In the Phase 1 part of this trial, the dose of cilengitide in combination with cisplatin, 5-FU and cetuximab was determined.

Cilengitide is an experimental anti-cancer substance interacting with so-called integrins. Integrins are protein molecules that are known to be present on the surface of certain cancer cells. Integrins are also found on certain cells that belong to growing blood vessels (endothelial cells). Integrins potentially facilitate the blood vessels' support of the tumor (angiogenesis) as well as the tumor's growth and further spread throughout the body (metastasis). By inhibiting integrins on the tumor cell surface, cilengitide potentially kills cancer cells, and potentially sensitizes cancer cells to other co-administered therapeutics. By inhibiting integrins on the endothelial cell surface, it potentially inhibits the ingrowth of additional blood vessels towards the tumor.

Cilengitide is given as an intravenous infusion (given by a drip in one vein of your arm). If any unacceptable side effect occurs, treatment with the study drug will be stopped.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00705016
Study type Interventional
Source Merck KGaA
Contact
Status Completed
Phase Phase 1/Phase 2
Start date October 2008
Completion date June 2013

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06398418 - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors Phase 1
Completed NCT01358097 - Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy N/A
Active, not recruiting NCT04116320 - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Phase 1
Completed NCT01721525 - Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) Phase 1
Completed NCT01016769 - Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Phase 1/Phase 2
Completed NCT00661427 - Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Phase 2
Completed NCT00382031 - Zalutumumab in Patients With Non-curable Head and Neck Cancer Phase 3
Recruiting NCT04391049 - Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Phase 1
Recruiting NCT05932511 - Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer Early Phase 1
Completed NCT00815295 - Study of Sorafenib/Cetuximab in Head and Neck Cancer Phase 1/Phase 2
Completed NCT00542308 - Zalutumumab in Non-curable Patients With SCCHN Phase 2
Completed NCT00485485 - Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer Phase 2
Terminated NCT02376699 - Safety Study of SEA-CD40 in Cancer Patients Phase 1
Completed NCT00255476 - The IRESSA Novel Head and Neck Chemotherapy Evaluation Study Phase 2
Recruiting NCT03935893 - Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Phase 2
Terminated NCT00401401 - Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer Phase 1/Phase 2
Terminated NCT00559351 - RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03509467 - Using MC1R Genotype to Impact Melanoma Risk Behavior N/A
Completed NCT01384708 - Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer Phase 0